id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-260340-dujd28gg	Chenoweth, Alicia M	Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs	2020-04-12		.txt	text/plain	10121	516	40	This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a "scaffolding" role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. Most therapeutic mAbs are IgG in origin and the heavy-chain subclass determines many of their biological properties including their long plasma half-life 3 ; complement activation, which is important in the action of some cytotoxic mAbs [4] [5] [6] and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FccR, the subject of this review. Therapy with an IgG1 anti-cancer cell mAb may then be compromised by the inhibitory action of FccRIIb upon the ITAM signaling of the activating FccR as both types of receptor would be coengaged on such an effector cell by the mAb bound to the target cell.	./cache/cord-260340-dujd28gg.txt	./txt/cord-260340-dujd28gg.txt